CRISPR (CRSP) & Vertex Complete BLA Submission for Exa-Cel
4/4 19:32
CRISPR Therapeutics CRSP and Vertex Pharmaceuticals VRTX completed the rolling submission of biologics license applications (BLAs) to the FDA for exagamglogene autotemcel (exa-cel) to treat sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT). The co...